AXA Framlington Biotech R Class Acc

Performance History30/04/2020
Growth of 1,000 (GBP) Advanced Graph
AXA Framlington Biotech R Class Acc
Fund-5.98.5-7.318.114.9
+/-Cat-1.9-1.70.6-2.17.0
+/-B’mrk0.3-2.6-4.1-2.16.5
 
Key Stats
NAV
22/05/2020
 GBX 226.70
Day Change -0.66%
Morningstar Category™ Sector Equity Biotechnology
IA (formerly IMA) Sector Specialist
ISIN GB0031007254
Fund Size (Mil)
30/04/2020
 GBP 444.62
Share Class Size (Mil)
22/05/2020
 GBP 118.57
Max Initial Charge 5.50%
Ongoing Charge
07/08/2019
  1.83%
Investment Objective: AXA Framlington Biotech R Class Acc
The aim of this Fund is to provide long-term capital growth. The Fund invests in shares of listed companies, principally in the biotechnology, genomic and medical research industry, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world, albeit the Fund tends to be biased towards the US as this is where the majority of biotechnology companies are based. The Fund may also invest in other transferable securities and units in collective investment schemes. The Fund may use derivatives for Efficient Portfolio Management. Use may be made of borrowing, cash holdings, hedging and other investment techniques permitted in the applicable Financial Conduct Authority rules.
Returns
Trailing Returns (GBP)22/05/2020
YTD22.61
3 Years Annualised12.58
5 Years Annualised4.96
10 Years Annualised17.66
12 Month Yield 0.00
Management
Manager Name
Start Date
Linden Thomson
05/07/2012
Dani Saurymper
01/04/2015
Inception Date
26/11/2001
Advertisement
Category Benchmark
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TR USDNASDAQ Biotechnology TR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNo
GrowthYes
IncomeNot Specific
HedgingNot Specific
OtherNot Specific
Portfolio Profile for  AXA Framlington Biotech R Class Acc31/03/2020
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock95.490.0095.49
Bond0.000.000.00
Property0.000.000.00
Cash3.540.103.44
Other1.070.001.07
Top 5 Regions%
United States88.61
Eurozone5.39
Asia - Emerging2.57
Europe - ex Euro2.53
United Kingdom0.89
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Biogen IncHealthcareHealthcare8.86
Amgen IncHealthcareHealthcare8.35
Regeneron Pharmaceuticals IncHealthcareHealthcare7.13
Gilead Sciences IncHealthcareHealthcare6.68
Vertex Pharmaceuticals IncHealthcareHealthcare5.05
AXA Framlington Biotech R Class Acc

Related

In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites